BCAL Diagnostics Ltd
ASX:BDX

Watchlist Manager
BCAL Diagnostics Ltd Logo
BCAL Diagnostics Ltd
ASX:BDX
Watchlist
Price: 0.11 AUD 4.76% Market Closed
Market Cap: 40.5m AUD

BCAL Diagnostics Ltd
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

BCAL Diagnostics Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
BCAL Diagnostics Ltd
ASX:BDX
Cash from Operating Activities
-AU$6.1m
CAGR 3-Years
-24%
CAGR 5-Years
-56%
CAGR 10-Years
N/A
Opthea Ltd
ASX:OPT
Cash from Operating Activities
-$158.6m
CAGR 3-Years
-31%
CAGR 5-Years
-95%
CAGR 10-Years
-41%
Mesoblast Ltd
ASX:MSB
Cash from Operating Activities
-$50m
CAGR 3-Years
9%
CAGR 5-Years
0%
CAGR 10-Years
N/A
CSL Ltd
ASX:CSL
Cash from Operating Activities
$3.6B
CAGR 3-Years
11%
CAGR 5-Years
7%
CAGR 10-Years
10%
Telix Pharmaceuticals Ltd
ASX:TLX
Cash from Operating Activities
AU$27.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
PYC Therapeutics Ltd
ASX:PYC
Cash from Operating Activities
-AU$51.6m
CAGR 3-Years
-33%
CAGR 5-Years
-55%
CAGR 10-Years
-35%
No Stocks Found

BCAL Diagnostics Ltd
Glance View

Market Cap
40.3m AUD
Industry
Biotechnology

BCAL Diagnostics Ltd. develops screening tests for the early detection of breast cancer. The company is headquartered in Sydney, New South Wales. The company went IPO on 2021-07-21. The firm is developing a blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, accurate and available to all women regardless of age, race and geographic location. The company has developed a non-invasive blood test for the detection of breast cancer. The firm is developing an in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from extracellular vehicles (EVs) from a patient's plasma or blood sample to diagnose the presence of cancer cells in a patient’s body. BCAL has partnered with integrated cancer care and cardiac provider GenesisCare to conduct clinical research required for regulatory approvals across jurisdictions.

BDX Intrinsic Value
0.3 AUD
Undervaluation 64%
Intrinsic Value
Price

See Also

What is BCAL Diagnostics Ltd's Cash from Operating Activities?
Cash from Operating Activities
-6.1m AUD

Based on the financial report for Jun 30, 2025, BCAL Diagnostics Ltd's Cash from Operating Activities amounts to -6.1m AUD.

What is BCAL Diagnostics Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-56%

Over the last year, the Cash from Operating Activities growth was -36%. The average annual Cash from Operating Activities growth rates for BCAL Diagnostics Ltd have been -24% over the past three years , -56% over the past five years .

Back to Top